Further advancements, such as those seen in the Bevacizumab Eliminates the Angiogenic Threat of ROP (BEAT-ROP) and Ranibizumab versus LPC for the treatment of very low birth weight infants with ROP (RAINBOW) trials, have demonstrated a reduced incidence of high myopia after anti-VEGF therapy compared to LPC in a two-year follow-up period [5,6]. Here, VEGFA is linked to retinopathy of prematurity.